Compare Marsh & McLennan Companies, Inc. (MRSH) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Tilray Brands Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.89 (market cap $84.39B), while Tilray Brands Inc trades at $4.2 (market cap $577.15M). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 146.2× Tilray Brands Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| MRSH | TLRY | |
|---|---|---|
Market Cap | $84.39B | $577.15M |
Sector | Financials | Health |
52-Week High | $207.02 | $21.00 |
52-Week Low | $157.32 | $3.88 |
Enterprise Value | $105.07B | $744.29M |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $180.52, down 2.81% on the day, with a bullish technical signal despite recent weakness. The company shows solid fundamentals with revenue growth to $26.98B in 2025 and consistent earnings beats. Analyst consensus is a Buy with a $208.63 price target, though sentiment is mixed with 66.7% Hold ratings. Recent news highlights expansion in cyber protection services and insights on healthcare cost trends.
The outlook remains positive given strong profitability and strategic initiatives, but risks include economic sensitivity and competitive pressures. The stock offers upside to the consensus target, supported by institutional interest and stable cash flows, though high valuation multiples warrant caution amid market volatility.
TLRY trades at $4.30, down 4.44% with a bearish technical outlook. The company reported record fiscal 2026 revenue of $915M but continues to post significant losses with a -13.27% net margin. Recent news highlights expansion in spirits distribution and medical cannabis production, though regulatory uncertainty weighs on sentiment. The stock trades below book value with a P/S of 0.51 and P/B of 0.36, suggesting potential undervaluation despite profitability challenges.
TLRY presents a high-risk opportunity with mixed signals. The discounted valuation and expanding beverage/alcohol business offer upside potential, but persistent losses, negative cash flow, and cannabis regulatory delays create substantial headwinds. Analyst consensus leans cautious with 65% hold ratings, reflecting the stock's speculative nature amid ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
